Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Astellas Pharma ( (JP:4503) ) is now available.
Astellas Pharma Inc. reported preliminary sales figures for its IZERVAY™ treatment for geographic atrophy secondary to age-related macular degeneration, totaling ¥15.9 billion or $110 million in the U.S. for the first quarter of FY2025. This announcement was made in conjunction with an investment community meeting, with further details to be discussed in the upcoming Q1 earnings call, highlighting the company’s ongoing efforts to strengthen its market position in ophthalmology.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas is a global life sciences company focused on providing transformative therapies in areas such as oncology, ophthalmology, urology, immunology, and women’s health. The company is dedicated to pioneering new healthcare solutions for diseases with high unmet medical needs through its research and development programs.
Average Trading Volume: 5,639,278
Technical Sentiment Signal: Sell
Current Market Cap: Yen2488.6B
For a thorough assessment of 4503 stock, go to TipRanks’ Stock Analysis page.